Antibody Dermatology Protein 
Pharmaceutical Technology
MAY 8, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.
pharmaphorum
OCTOBER 5, 2022
Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. The aim will be to identify promising candidates in areas of “unmet patient need.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 18, 2022
The use of monovalent degraders, which enable the targeted degradation of disease-relevant proteins, offers a new avenue to reach tissue that cannot be targeted with conventional therapeutic agents. Researchers at Almirall have identified several proteins whose abnormal function is associated with inflammatory immune skin diseases.
pharmaphorum
SEPTEMBER 30, 2022
The Spanish drugmaker is paying $15 million upfront for rights to IL-2 mutant fusion protein (IL-2 mu-Fc) SIM0278 outside the Greater China region, with another $492 million pledged in development and commercial milestone payments if the drug works across multiple autoimmune indications. . Last year, Merck & Co paid $1.85
The Pharma Data
MARCH 27, 2022
More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Eli Lilly and Company (NYSE: LLY) announced today at the American Academy of Dermatology (AAD) Annual Meeting.
The Pharma Data
AUGUST 16, 2021
Lebrikizumab is a novel monoclonal antibody (mAb) that binds soluble IL-13 with high affinity, has high bioavailability, a long half-life and blocks IL-13 signaling. associate professor of dermatology at George Washington University School of Medicine and Health Sciences in Washington, DC, and a principal investigator of the ADvocate 2 trial.
The Pharma Data
JANUARY 24, 2021
It includes adults with confirmed COVID-19 on supplemental oxygen or mechanical ventilation with abnormal levels of at least two serum biomarkers, C reactive protein, D dimer, lactate dehydrogenase, or ferritin. All participants randomized to receive either 4,200 mg of bamlanivimab, Lilly’s neutralizing antibody, or placebo.
Expert insights. Personalized for you.
246 
Let's personalize your content